MedTrace Logo

Evaluation of Atorvastatin on Atherosclerosis Composition

NCT00576576 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2013-12-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of Atorvastatin on the coronary atherosclerosis plaque morphology.

Conditions

Interventions

DRUG

Atorvastatin

Atorvastatin 80 mg a day

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • Habib Samady, MD · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00576576 on ClinicalTrials.gov